The United States has launched a tariff investigation targeting Germany's pharmaceutical industry, a move that risks deepening trade tensions with the European Union and disrupting global medicine supply chains. The probe, announced by the US government, could lead to new duties on a wide range of German-made drugs and medical products.
Why Germany's pharma sector is in the crosshairs
The investigation focuses on whether German pharmaceutical imports threaten US national security or harm domestic manufacturers. Washington has not detailed the specific complaints, but the probe comes amid a broader push by the Biden administration to reshore critical industries and reduce reliance on foreign suppliers. Germany is Europe's largest drug producer, home to companies like Bayer and Merck KGaA, though those firms are not named in the investigation itself.
German pharmaceutical exports to the US were worth roughly $20 billion last year, covering everything from cancer treatments to over-the-counter painkillers. Any tariffs could raise costs for American hospitals and patients, though the exact scope of affected products remains unclear.
Ripple effects for US-EU relations
The investigation threatens to reopen old wounds between Washington and Brussels. The two sides have clashed repeatedly over steel and aluminum tariffs, aircraft subsidies, and digital taxes. EU officials have already signaled they are preparing retaliatory measures should the US impose new duties on German drugs. Possible countermeasures include tariffs on US agricultural goods, machinery, or chemicals.
“We will not hesitate to defend our interests,” a European Commission spokesperson said, according to reports. The EU has previously used similar threats to pressure the US into trade talks.
The probe also complicates ongoing efforts to coordinate on China trade and technology policy. Both the US and EU have sought a united front against Beijing, but such disputes undercut that cooperation.
What the probe could mean for drug prices
If tariffs are imposed, the immediate impact would likely be higher prices for German-imported prescription drugs. US patients already face some of the highest medicine costs in the world. Additional tariffs could push those costs up further, especially for specialty drugs with few alternatives.
But the investigation could also accelerate efforts by German pharmaceutical companies to move some production to the US or partner with American firms. Several European drugmakers have already expanded factories in the United States to avoid trade barriers.
The US government has not set a timeline for the investigation's conclusion. Public hearings and comment periods are expected in the coming months. Meanwhile, German officials are expected to lobby against the probe, arguing it could harm both economies and delay life-saving medicines.
